What is 23.4% w/v SODIUM CHLORIDE INJECTION USP
23.4% Sodium Chloride Injection USP is a highly concentrated, sterile solution of sodium chloride (NaCl) in water for injection. It is intended for intravenous administration in a controlled hospital setting, typically as an adjunctive agent for the management of severe sodium deficits (hyponatremia), fluid imbalances, or as a component of parenteral nutrition or specialized electrolyte formulations. This solution contains 234 mg of sodium chloride per mL, equating to 4 mEq of sodium and chloride per mL.
- Concentration: 23.4% w/v (weight/volume), making it a hypertonic solution.
- Form: Infusion/Solution for Injection.
- Packaging: 50 ml Polyethylene Bag.
- Active Ingredient: Sodium Chloride – a critical electrolyte involved in maintaining osmotic pressure, fluid balance, and nerve conduction.
This preparation is not intended for direct infusion without prior dilution and must be used under strict medical supervision due to the risks of hypernatremia and vascular irritation.
How to use 23.4% w/v SODIUM CHLORIDE INJECTION USP
Due to its hypertonic nature, 23.4% Sodium Chloride Injection must be used with great caution. The solution is primarily used as a concentrated source of sodium in large-volume parenteral solutions or for correcting acute hyponatremia in critically ill patients.
- Administration Route: Intravenous (IV) only, after proper dilution.
- Dilution Requirement: Must be diluted before administration; never use undiluted due to the risk of serious vascular damage.
- Infusion Method: Typically added to compatible IV fluids such as Dextrose or normal saline under sterile conditions.
- Monitoring: Continuous monitoring of serum sodium levels, fluid balance, and overall electrolyte status is essential during administration.
- Professional Oversight: Only trained healthcare providers should handle and administer this product.
The infusion rate and final volume should be determined based on the patient’s individual electrolyte requirements and clinical condition.
Mode of Action 23.4% w/v SODIUM CHLORIDE INJECTION USP
The therapeutic effect of 23.4% Sodium Chloride Injection is primarily due to its hypertonic sodium content, which directly influences plasma osmolality and fluid distribution within the body.
- Osmotic Effect: The high concentration of sodium exerts an osmotic force that draws water out of intracellular spaces into the extracellular compartment, thereby expanding plasma volume.
- Electrolyte Repletion: Provides a rapid and concentrated source of sodium and chloride ions, essential for cellular function, electrical conduction in nerves and muscles, and maintenance of acid-base balance.
- Correction of Hyponatremia: Used in critical care to manage acute symptomatic hyponatremia, particularly when water restriction alone is insufficient.
- Vascular Support: Increases intravascular volume in hypovolemic states when used as part of larger fluid therapy protocols.
By influencing fluid distribution and correcting electrolyte imbalances, it stabilizes vital cellular processes and supports cardiovascular and neurological functions.
23.4% w/v SODIUM CHLORIDE INJECTION USP Interactions 23.4% w/v SODIUM CHLORIDE INJECTION USP
Although 23.4% Sodium Chloride Injection is a simple electrolyte solution, it may interact with other drugs, especially those affecting fluid and electrolyte balance.
- Diuretics: Use with potassium-wasting diuretics (e.g., furosemide) may exacerbate electrolyte imbalances. Conversely, potassium-sparing diuretics (e.g., spironolactone) can reduce renal sodium elimination.
- Corticosteroids: May cause sodium and fluid retention, amplifying the effects of sodium chloride.
- Antihypertensives: Volume expansion from sodium administration may reduce the efficacy of antihypertensive therapy.
- Lithium: Sodium intake affects lithium excretion and plasma levels. Increased sodium can lead to decreased lithium efficacy.
- Calcium or Magnesium-containing solutions: Mixing without compatibility assessment can result in precipitation or loss of therapeutic effect.
Drug compatibility should be assessed before mixing with other solutions. Always consult compatibility charts or a pharmacist when co-administering with other parenteral medications.
Dosage of 23.4% w/v SODIUM CHLORIDE INJECTION USP
The dosage of 23.4% Sodium Chloride Injection is individualized based on the patient’s clinical condition, severity of hyponatremia, and laboratory findings.
- General Dosing Guideline: Administer only after dilution. Typical dosages are based on the desired sodium correction (e.g., mEq of sodium required).
- For Hyponatremia: A commonly used approach involves calculating sodium deficit using the formula: Sodium Deficit = (Desired Na+ - Current Na+) × Total Body Water.
- Infusion Rate: Should not exceed 0.5 mEq/L/hr in chronic hyponatremia or 1 mEq/L/hr in acute symptomatic cases to avoid central pontine myelinolysis.
- Maximum Daily Dose: Should be carefully controlled to avoid sodium overload and hypernatremia.
- Administration: Slow IV infusion via a central line is preferred due to its hyperosmolar nature.
Dose adjustments must be made frequently based on lab results and patient response. Rapid corrections can have serious neurological consequences.
Possible side effects of 23.4% w/v SODIUM CHLORIDE INJECTION USP
While essential for specific clinical situations, 23.4% Sodium Chloride Injection carries a high risk of adverse effects due to its hypertonicity.
- Hypernatremia: The most significant risk; symptoms include restlessness, irritability, lethargy, muscle twitching, and in severe cases, seizures or coma.
- Fluid Overload: May cause edema, hypertension, or pulmonary congestion, especially in patients with renal or cardiac dysfunction.
- Local Irritation: Pain, redness, or phlebitis at the injection site if administered through peripheral veins.
- Osmotic Demyelination Syndrome (ODS): Risk when correcting chronic hyponatremia too rapidly.
- Metabolic Disturbances: Hyperchloremic metabolic acidosis can occur due to excess chloride ions.
Patients receiving this solution must be monitored closely for clinical and laboratory signs of adverse effects. Immediate action is required if symptoms of sodium overload appear.
23.4% w/v SODIUM CHLORIDE INJECTION USP Contraindications 23.4% w/v SODIUM CHLORIDE INJECTION USP
Use of 23.4% Sodium Chloride Injection is contraindicated in certain conditions where sodium or fluid overload would pose serious health risks.
- Hypernatremia: Absolute contraindication as it would worsen sodium overload.
- Severe Renal Impairment: Risk of fluid retention and inability to excrete excess sodium.
- Congestive Heart Failure (CHF): Risk of fluid overload and pulmonary edema.
- Severe Hypertension: Sodium may exacerbate elevated blood pressure.
- Peripheral or Pulmonary Edema: Increased sodium and fluid may worsen edema.
- Incompatibility: Should not be administered concurrently with incompatible drugs or solutions without prior dilution and mixing assessment.
This solution must not be used unless the anticipated benefit outweighs the potential risks in vulnerable populations.
Storage of 23.4% w/v SODIUM CHLORIDE INJECTION USP
Proper storage conditions are crucial to maintain the sterility and chemical stability of 23.4% Sodium Chloride Injection.
- Storage Temperature: Store at controlled room temperature, between 15°C to 25°C (59°F to 77°F).
- Avoid Freezing: Do not freeze, as this may cause container integrity issues or precipitation of salts.
- Container Integrity: Use only if the solution is clear and the container is intact. Inspect for leaks or discoloration before use.
- Light Protection: Generally stable in normal light; no special light protection required.
- Shelf Life: Follow expiration date indicated on the packaging. Discard any unused portion after opening.
Ensure proper inventory rotation (first-expiry-first-out) in healthcare settings to minimize waste and ensure safety.
23.4% w/v SODIUM CHLORIDE INJECTION USP features an exceptional active ingredient renowned for its potent effects, comprising Sodium chloride. This powerful formulation provides a superior solution for addressing diverse health concerns. With 234mg/ml concentration and an easily manageable Infusion/Solution for, it remains a preferred option for countless individuals seeking effective treatment.
Introduction
All you need to know about 23.4% w/v SODIUM CHLORIDE INJECTION USP .
Welcome to Dwaey, specifically on 23.4% w/v SODIUM CHLORIDE INJECTION USP page.
This medicine contains an important and useful components, as it consists of Sodium chloride.
23.4% w/v SODIUM CHLORIDE INJECTION USP is available in the market in concentration 234mg/ml and in the form of Infusion/Solution for.
QATAR PHARMA is the producer of 23.4% w/v SODIUM CHLORIDE INJECTION USP and it is imported from QATAR,
The most popular alternatives of 23.4% w/v SODIUM CHLORIDE INJECTION USP are listed downward .
-
Active Substance
-
Size
-
Indications
-
Type
-
Company
Frequently Asked Questions
23.4% w/v SODIUM CHLORIDE INJECTION USP should be stored according to the instructions provided by QATAR PHARMA.
In general, it is recommended to store 23.4% w/v SODIUM CHLORIDE INJECTION USP in a cool, dry place, away from direct sunlight
and out of the reach of children.
The duration of treatment with 23.4% w/v SODIUM CHLORIDE INJECTION USP may vary depending on the condition being treated
and the guidance of your healthcare provider. It is important to follow the prescribed treatment
plan and continue taking 23.4% w/v SODIUM CHLORIDE INJECTION USP for the recommended duration, even if your symptoms improve.
If you have any concerns or questions about the duration of treatment, consult your healthcare provider.
It is important to check with your healthcare provider or read the medication label for specific
instructions regarding alcohol consumption while taking 23.4% w/v SODIUM CHLORIDE INJECTION USP. Some medications, including
23.4% w/v SODIUM CHLORIDE INJECTION USP, may have interactions with alcohol that can reduce effectiveness, increase side
effects, or pose other risks to your health. It is best to follow the guidance provided by your
healthcare professional.
If you miss a dose of 23.4% w/v SODIUM CHLORIDE INJECTION USP, take it as soon as you remember. However, if it is close
to the time for your next scheduled dose, skip the missed dose and continue with your regular dosing
schedule. Do not take a double dose to make up for a missed one unless advised by your healthcare provider.
No, do not stop taking 23.4% w/v SODIUM CHLORIDE INJECTION USP without consulting your healthcare provider, even if your
symptoms improve. It is important to complete the full course of treatment as prescribed. Stopping
the medication prematurely may lead to a relapse or incomplete resolution of the condition. If you
have concerns about the duration of treatment, consult your healthcare provider for guidance.
It is important to consult your healthcare provider before taking 23.4% w/v SODIUM CHLORIDE INJECTION USP if you are
pregnant or breastfeeding. They will be able to assess the potential risks and benefits based on your
specific situation. Please note that the safety and suitability of 23.4% w/v SODIUM CHLORIDE INJECTION USP during pregnancy
or breastfeeding may depend on the active substance [Active Substance], concentration 234mg/ml,
and the specific recommendations of QATAR PHARMA.
The effects of 23.4% w/v SODIUM CHLORIDE INJECTION USP on your ability to drive or operate machinery can vary depending on
the active substance [Active Substance], concentration 234mg/ml, and individual factors.
Some medications may cause drowsiness, dizziness, or other side effects that can impair your judgment
or coordination. It is important to read the medication label or consult your healthcare provider to
understand any potential effects on your ability to perform tasks that require alertness.
The instructions for taking 23.4% w/v SODIUM CHLORIDE INJECTION USP with or without food may vary depending on the medication
and the recommendations of QATAR PHARMA. Some medications may be more effective when taken with
food to enhance absorption or reduce stomach irritation, while others may need to be taken on an empty
stomach for optimal absorption. Read the medication label or consult your healthcare provider for specific instructions.
The use of 23.4% w/v SODIUM CHLORIDE INJECTION USP in children or elderly individuals may depend on various factors, including
the specific medication, type Infusion/Solution for, and the recommendations of QATAR PHARMA. Some
medications may have specific dosing instructions or precautions for these age groups. Consult your
healthcare provider or read the medication label for information regarding the safe and appropriate use
of 23.4% w/v SODIUM CHLORIDE INJECTION USP in children or elderly individuals.
Dwaey
All medical information published on the Dwaey website aims to increase medical awareness and health education among users. However, it is not a substitute for professional medical advice. Always consult with a specialist doctor. We strongly advise against using any information or medicine found on the site without referring to your healthcare provider.
Related Products
0 Comments